检索结果-南通市图书馆

Incidence and prognosis of olfactory and gustatory dysfunctions related to SARS-CoV-2 Omicron strain infection in china:A national multicenter survey of 35,566 individuals

在线全文

学校读者我要写书评

暂无评论

World Journal of Otorhinolaryngology-Head and Neck Surgery 2024年第2期10卷 113-120页

作者： Meng-Fan liu Rui-Xia Ma Xian-Bao Cao Hua Zhang Shui-hong Zhou Wei-hong jiang Yan jiang Jing-Wu Sun Qin-Tai Yang Xue-Zhong li Ya-Nan Sun li Shi Min Wang Xi-Cheng Song Fu-Quan Chen Xiao-Shu Zhang hong-Quan Wei Shao-Qing Yu Dong-Dong Zhu Luo Ba Zhi-Wei Cao Xu-ping Xiao Xin Wei Zhi-hong lin Feng-hong Chen Chun-Guang Shan Guang-Ke Wang Jing Ye Shen-hong Qu chang-Qing Zhao zhen-lin Wang Hua-Bin li Feng liu Xiao-Bo Cui Sheng-Nan Ye zheng liu Yu Xu Xiao Cai Wei Huang Ru-Xin Zhang Yu-lin Zhao Guo-Dong Yu Guang-Gang Shi Mei-ping Lu Yang Shen Yu-Tong Zhao Jia-hong Pei Shao-Bing Xie Long-Gang Yu Ye-Hai liu Shao-Wei Gu Yu-Cheng Yang Lei Cheng jian-Feng liu Graduate School of Beijing university of Chinese medicine BeijingChina department of Otorhinolaryngology Head and Neck Surgery China-Japan Friendship HospitalBeijingChina department of Otorhinolaryngology Head and Neck Surgery The First People's Hospital of YinchuanYinchuanChina department of Otorhinolaryngology The First People's Hospital of Yunnan ProvinceKunmingChina department of Otorhinolaryngology The First Affiliated Hospital of Xinjiang Medical UniversityUrumqiChina department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina department of Otorhinolaryngology Head and Neck Surgery Xiangya Hospital Central South UniversityChangshaChina department of Otorhinolaryngology Head and Neck Surgery The Affiliated Hospital of Qingdao UniversityQingdaoChina department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of USTCHefeiChina department of Otorhinolaryngology Head and Neck Surgery The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina department of Otorhinolaryngology Head and Neck Surgery Qilu Hospital of Shandong UniversityJinanChina department of Otorhinolaryngology Head and Neck Surgery The Second Affiliated Hospital of Harbin Medical UniversityHarbinChina department of Otolaryngology The Second Hospital of Shandong UniversityShandong UniversityJinanChina department of Otorhinolaryngology Head and Neck Surgery Peking University People's HospitalBeijingChina department of Otorhinolaryngology Head and Neck Surgery Yantai Yuhuangding HospitalQingdao UniversityYantaiChina department of Otorhinolaryngology Head and Neck Surgery Xijing HospitalThe Fourth Military Medical UniversityXi'anChina Gansu Provincial Center for Disease Control and Prevention LanzhouChina department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of China Medical UniversityShenyangChina department of Otorhinolaryngology Head and Neck Surgery Tongji Hospit

Objective:This cross-sectional study aimed to determine the epidemiology of olfactory and gustatory dysfunctions related to COVID-19 in ***:This study was conducted by 45 tertiary Grade-A hospitals in *** and offline questionnaire data were obtained from patients infected with COVID-19 between December 28,2022,and February 21,*** collected information included basic demographics,medical history,smoking and drinking history,vaccination history,changes in olfactory and gustatory functions before and after infection,and other postinfection symptoms,as well as the duration and improvement status of olfactory and gustatory ***:Complete questionnaires were obtained from 35,566 *** overall incidence of olfactory and taste dysfunction was 67.75%.Being female or being a cigarette smoker increased the likelihood of developing olfactory and taste *** received four doses of the vaccine or having good oral health or being a alcohol drinker decreased the risk of such *** infection,the average olfactory and taste VAS scores were 8.41 and 8.51,respectively;after infection,they decreased to 3.69 and 4.29 and recovered to 5.83 and 6.55 by the time of the *** median duration of dysosmia and dysgeusia was 15 and 12 days,respectively,with 0.5%of patients having symptoms lasting for more than 28 *** overall self-reported improvement rate was 59.16%.Recovery was higher in males,never smokers,those who received two or three vaccine doses,and those that had never experienced dental health issues,or chronic accompanying ***:The incidence of dysosmia and dysgeusia following infection with the SARS-CoV-2 virus is high in *** and prognosis are influenced by several factors,including sex,SARS-CoV-2 vaccination,history of head-facial trauma,nasal and oral health status,smoking and drinking history,and the persistence of accompanying symptoms.

关键词： epidemiologic studies incidence olfactory disorders prognosis SARS-CoV-2 taste disorders

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao jianshe Cao Antoine Chance Xuejun chang Yue chang zhe chang Xinyuan chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong jianin AGH university of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied Physics department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced Science and Technology Beijing china Institute of Atomic Energy Beijing china Jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of Mining and Technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu university DalianLiaoning Dalian university of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East china university Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military medical Research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng Ying-Hui Jin Tong-Zu liu Fang-Ming Chen De-Gang Ding Meng Fu Xin-Quan Gu Bang-Min Han Xing Huang Zhi Hou Wan-li Hu Xin-li kang Gong-Hui li jian-Xing li Pei-Jun li Chao-Zhao liang Xiu-Heng liu Zhi-Yu liu Chun-Xiao liu Jiu-Min liu Guang-Heng Luo Yi Luo Wei-Jun Qin jian-hong Qiu jian-Xin Qiu Xue-Jun Shang Ben-kang Shi Fa Sun Guo-Xiang Tian Ye Tian Feng Wang Feng Wang Yin-Huai Wang Yu-Jie Wang Zhi-ping Wang Zhong Wang Qiang Wei Min-Hui Xiao Wan-Hai Xu Fa-Xian Yi Chao-Yang Zhu Qian-Yuan Zhuang li-Qun Zhou Xiao-Feng Zou Nian-Zeng Xing Da-lin He Xing-Huan Wang 无 department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China Center for Evidence-Based and Translational medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China department of Urology Qinghai University Affiliated HospitalXi’ning810012China department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China department of Urology

Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia Recommendation Treatment Guideline

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in china： A Prospective, Multicenter, Noninterventional Study

在线全文

学校读者我要写书评

暂无评论

Chinese medical Journal 2018年第15期131卷 1767-1775页

作者： jian-Qiu Wu Yong-ping Song li-ping Su Ming-Zhi Zhang Wei li Yu Hu Xiao-hong Zhang Yu-Huan Gao zuo-Xing Niu Ru FengTM Wei Wang Jie-Wen Peng Xiao-lin li Xue-Nong Ouyang chang-ping Wu Wei-Jing Zhang Yun Zeng zhen Xiao Ying-Min liang Yong-Zhi Zhuang Ji-Shi Wang Zi-Min Sun Hai Bai Tong-jian Cui Ji-Feng Feng department of Oncology Jiangsu Cancer Hospital ＆ Jiangsu Institute of Cancer Research ＆ Nanjing Medical University Affiliated Cancer HospitalNanjing Jiangsu 210008China department of Hematology Henan Cancer HospitalZhengzhouHenan 450000China department of Hematology Shanxi Cancer HospitalTaiyuanShanxi 030013China department of Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450000China department of Oncology Jilin University First Affiliated HospitalChangchunJilin 130000China department of Hematology Union Hospital Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430072China department of Hematology The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310009China department of Hematology Fourth Hospital of Hebei Medical UniversityShijiazhuangHebei 050000China department of Oncology Affiliated Hospital of Shandong Academy of Medical SciencesJinanShandong 250000China department of Hematology Medical University Nanfang HospitalGuangzhouGuangdong 510000China department of Oncology Guangdong Foshan First HospitalFoshanGuangdong 528000China department of Oncology Guangdong Zhongshan People＇s HospitalZhongshanGuangdong 528403China department of Hematology Xiangya Hospital Central South UniversityChangshaHunan 410008China department of Oncology Fuzhou General Hospital of Nanjing Military CommandFuzhouFujian 350001China department of Oncology Changzhou First People＇s HospitalChangzhouJiangsu 213000China department of Oncology 307 Hospital of Chinese People＇s Liberation ArmyBeijing 100070China Tdepartment of Hematology First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650221China department of Hematology Affiliated Hospital of Neimenggu Medical CollegeHohhotHuhehaoteInner Mongolia 010050China department of Hematology The Fourth Military Medical University Affiliated Tangdu HospitalXi＇anShaanxi 710038China department of Oncology Daqing General Hospital Grou

Background： Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma （DLBCL） or follicular lymphoma （FL） are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes ofrituximab plus chemotherapy （R-chemo） as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus （HBV） reactivation management was also investigated. Methods： A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in china was conducted between January 17, 2011 and October 31, 2016. Enrolled patients underwent safety and effectiveness assessments after the last rituximab dose and were followed up for 3 years. Effectiveness endpoints included progression-free survival （PFS） and overall survival （OS）. Safety endpoints were adverse events （AEs）, serious AEs, drug-related AEs, and AEs of special interest. We also reported data on the incidence of HBV reactivation. Results： In total, 283 previously untreated CD20-positive DLBCL and 31 FL patients from 24 centers were enrolled. Three-year PFS was 59% （95% confidence interval [CI]： 50-67%） for DLBCL patients and 46% （95% CI： 20-69%） for FL patients. For DLBCL patients, multivariate analyses showed that PFS was not associated with international prognostic index, tumor maximum diameter, HBV infection status, or number ofrituximab treatment cycles, and OS was only associated with age 〉60 years （P 〈 0.05）. R-chemo was well tolerated. The incidence of HBV reactivation in hepatitis B surface antigen （HBsAg）-positive and HBsAg-negative/hepatitis B core antibody-positive patients was 13% （3/24） and 4% （3/69）, respectively. Conclusions： R-chemo is effective and safe in real-world clinical practice as first-line treatment for DLBCL and FL in china, and that HBV reactivation during R-chemo is manageable with preventive measur

关键词： Asian Hematopoietic Malignancy Hepatitis B Virus Observational Study Rituximab

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第1期6卷 95-104页

作者： Ke Wang Wei Chen zheng Zhang Yongqiang Deng jian-Qi lian Peng Du Ding Wei Yang Zhang Xiu-Xuan Sun li Gong Xu Yang Lei He Lei Zhang Zhiwei Yang Jie-Jie Geng Ruo Chen Hai Zhang Bin Wang Yu-Meng Zhu Gang Nan jian-li jiang ling li Jiao Wu Peng lin Wan Huang liangzhi Xie Zhao-Hui zheng Kui Zhang Jin-lin Miao hong-Yong Cui Min Huang Jun Zhang ling Fu Xiang-Min Yang Zhongpeng Zhao Shihui Sun hongjing Gu zhe Wang Chun-Fu Wang Yacheng Lu Ying-Ying liu Qing-Yi Wang Huijie Bian ping ZhuZhi-Nan Chen National Translational Science Center for Molecular medicine&department of Cell Biology Fourth Military Medical UniversityXi’an 710032China Beijing Institute of Biotechnology Beijing 100071China State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and EpidemiologyBeijing 100071China Tangdu Hospital Fourth Military Medical UniversityXi’an 710038China MOE Key Laboratory for Nonequilibrium Synthesis and Modulation of Condensed Matter Xi’an Jiaotong UniversityXi’an 710049China Sino Biological Inc. Beijing 100176China department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi’an 710032China School of Basic medicine Fourth Military Medical UniversityXi’an 710032China

In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2,no specific and effective drugs for treating this disease have been reported until ***-converting enzyme 2(ACE2),a receptor of SARS-CoV-2,mediates the virus infection by binding to spike *** ACE2 is expressed in the lung,kidney,and intestine,its expressing levels are rather low,especially in the *** the great infectivity of COVID-19,we speculate that SARS-CoV-2 may depend on other routes to facilitate its ***,we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike *** loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody,Meplazumab,inhibits SARSCoV-2 *** of human CD147 allows virus entry into non-susceptible BHK-21 cells,which can be neutralized by CD147 extracellular *** loads are detectable in the lungs of human CD147(hCD147)mice infected with SARS-CoV-2,but not in those of virus-infected wild type ***,virions are observed in lymphocytes of lung tissue from a COVID-19 *** T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dosedependent manner,which is specifically inhibited by ***,CD147 mediates virus entering host cells by ***,our study reveals a novel virus entry route,CD147-spike protein,which provides an important target for developing specific and effective drug against COVID-19.

关键词： ACE2 CD147 intestine

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-liang li Ming-Sheng Huang Wei-Zhu Yang Guo-Wen Yin Bin-Yan Zhong Jun-Hui Sun Zhi-Cheng Jin jian-jian Chen Nai-jian Ge Wen-Bin Ding Wen-Hui li Jin-Hua Huang Wei Mu Shan-Zhi Gu Jia-ping li Hui Zhao Shu-Wei Wen Yan-Ming Lei Yu-Sheng Song Chun-Wang Yuan Wei-Dong Wang Ming Huang Wei Zhao jian-Bing Wu Song Wang Xu Zhu jian-Jun Han Wei-Xin Ren Zai-Ming Lu Wen-Ge Xing Yong Fan Hai-Lan lin Zi-Shu Zhang Guo-Hui Xu Wen-Hao Hu Qiang Tu hong-Ying Su Chuan-Sheng zheng Yong Chen Xu-Ya Zhao Zhu-Ting Fang Qi Wang Jin-Wei Zhao Ai-Bing Xu jian Xu Qing-Hua Wu Huan-Zhang Niu jian Wang Feng Dai Dui-ping Feng Qing-Dong li Rong-Shu Shi Jia-Rui li Guang Yang Hai-Bin Shi jian-Song Ji Yu-E liu zheng Cai Po Yang Yang Zhao Xiao-li Zhu li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China department of Interventional Radiology Nantong First People’s HospitalNantong 226001China department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2009年第22期15卷 2731-2738页

作者： li-Jing Zhang Shi-Yan Wang Xiao-Hui huo zhen-Long Zhu jian-Kun Chu Jin-Cheng Ma Dong-Sheng Cui ping Gu Zeng-Ren Zhao Ming-Wei Wang Jun Yu department of Gastroenterology the First Affiliated Hospital of Hebei Medical University Shijiazhuang 050051 Hebei Province China department of medicine and Therapeutics the Prince of Wales Hospital the Chinese University of Hong Kong Hong Kong China department of Pathology the First Affiliated Hospital of Hebei Medical University Shijiazhuang 050051 Hebei Province China department of Neurology the First Affiliated Hospital of Hebei Medical University Shijiazhuang 050051 Hebei Province China department of Surgery the First Affiliated Hospital of Hebei Medical University Shijiazhuang 050051 Hebei Province China

AIM： To evaluate whether celecoxib, a selective cyclooxygenase 2 （COX-2） inhibitor, could reduce the severity of gastric precancerous lesions following Hel/cobacter pylori （H pylorl） eradication. METHODS： H pylori-eradicated patients with gastric precancerous lesions randomly received either celecoxib （n = 30） or placebo （n = 30） for up to 3 mo. COX-2 expression and activity was determined by immunostaining and prostaglandin E2 （PGE2） assay, cell proliferation by Ki-67 immunostaining, apoptosis by TUNEL staining and angiogenesis by microvascular density （MVD） assay using CD31 ***： COX-2 protein expression was significantly increased in gastric precancerous lesions （atrophy, intestinal metaplasia and dysplasia, respectively） compared with chronic gastritis, and was concomitant with an increase in cell proliferation and angiogenesis. A significant improvement in precancerous lesions was observed in patients who received celecoxib compared with those who received placebo （P 〈 0.001）. Of these three changes, 84.6% of sites with dysplasia regressed in patients treated with celecoxib （P = 0.002） compared with 60% in the placebo group, suggesting that celecoxib was effective on the regression of dysplasia. COX-2 protein expression （P 〈 0.001） and COX-2 activity （P 〈 0.001） in the gastric tissues were consistently lower in celecoxib-treated patients compared with the placebo-treated subjects. Moreover, it was also shown that celecoxib suppressed cell proliferation （P 〈 0.01）, induced cell apoptosis （P 〈 0.01） and inhibited angiogenesis with decreased MVD （P 〈 0.001）. However, all of these effects were not seen in placebo-treated subjects. Furthermore, COX-2 inhibition resulted in the up-regulation of PPARy expression, a protective molecule with anti-neoplastic effects. CONCLUSION： H pylori eradication therapy followed by celecoxib treatment improves gastric precancerous lesions by inhibiting COX-2 activity, inducing apoptosis, and suppressing cell proliferation

关键词： Apoptosis Cyclooxygenase 2 Gastric precancerous lesions Helicobacter pylori Microvessel density Proliferation

The DIRECT consortium and the REST-meta-MDD project:towards neuroimaging biomarkers of major depressive disorder

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Psychoradiology 2022年第1期2卷 32-42页

作者： Xiao Chen Bin Lu Hui-Xian li Xue-Ying li Yu-Wei Wang Francisco Xavier Castellanos li-ping Cao Ning-Xuan Chen Wei Chen Yu-Qi Cheng Shi-Xian Cui Zhao-Yu Deng Yi-Ru Fang Qi-Yong Gong Wen-Bin Guo zheng-Jia-Yi Hu li Kuang Bao-Juan li Le li Tao li Tao lian Yi-Fan liao Yan-Song liu zhe-Ning liu jian-ping Lu Qing-Hua Luo Hua-Qing Meng Dai-Hui Peng jiang Qiu Yue-Di Shen Tian-Mei Si Yan-Qing Tang Chuan-Yue Wang Fei Wang Hua-Ning Wang Kai Wang Xiang Wang Ying Wang Zi-Han Wang Xiao-ping Wu Chun-Ming Xie Guang-Rong Xie Peng Xie Xiu-Feng Xu hong Yang jian Yang Shu-Qiao Yao Yong-Qiang Yu Yong-Gui Yuan Ke-Rang Zhang Wei Zhang Zhi-Jun Zhang Jun-Juan Zhu Xi-Nian zuo Jing-ping Zhao Yu-Feng Zang the DIRECT consortium Chao-Gan Yan CAS Key Laboratory of Behavioral Science Institute of PsychologyChinese Academy of SciencesBeijing 100101China International Big-Data Center for Depression Research Chinese Academy of SciencesBeijing 100101China Magnetic Resonance Imaging Research Center Institute of PsychologyChinese Academy of SciencesBeijing 100101China department of Psychology University of Chinese Academy of SciencesBeijing 100049China Sino-Danish College University of Chinese Academy of SciencesBeijing 101408China Sino-Danish Center for Education and Research Graduate University of Chinese Academy of SciencesBeijing 101408China department of Child and Adolescent Psychiatry NYU Grossman School of MedicineNew YorkNY 10016USA Nathan Kline Institute for Psychiatric Research OrangeburgNew YorkNY 10962USA 9Affiliated Brain Hospital of Guangzhou Medical UniversityGuangzhou 510370China Capital Normal university Beijing 100089China department of Psychiatry Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou 310020ZhejiangChina department of Psychiatry First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650032China Shanghai Mental Health Center Shanghai Jiao Tong University School of MedicineShanghai 200030China Huaxi MR Research Center(HMRRC) Department of RadiologyWest China Hospital of Sichuan UniversityChengduSichuan 610044China Research Unit of Psychoradiology Chinese Academy of Medical SciencesChengduSichuan 610052China department of Psychiatry and National Clinical Research Center for Mental DisordersThe Second Xiangya Hospital of Central South UniversityChangsha 410011HunanChina department of Psychiatry The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400042China Xijing Hospital of Air Force Military medical university Xi’anShaanxi 710032China Center for Cognitive Science of Language Beijing Language and Culture UniversityBeijing 100083China Affiliated Mental Health Center&Hangzhou Seventh People’s Hospital Zhejiang University School of

Despite a growing neuroimaging literature on the pathophysiology of major depressive disorder(MDD),repro-ducible findings are lacking,probably reflecting mostly small sample sizes and heterogeneity in analytic *** address these issues,the Depression Imaging REsearch ConsorTium(DIRECT)was *** REST-meta-MDD project,pooling 2428 functional brain images processed with a standardized pipeline across all participating sites,has been the first effort from *** this review,we present an overview of the moti-vations,rationale,and principal findings of the studies so far from the REST-meta-MDD *** from the first round of analyses of the pooled repository have included alterations in functional connectivity within the default mode network,in whole-brain topological properties,in dynamic features,and in functional *** well-powered exploratory observations have also provided the basis for future longitudinal hypothesis-driven *** these fruitful explorations,DIRECT has proceeded to its second stage of data sharing that seeks to examine ethnicity in brain alterations in MDD by extending the exclusive Chinese original sample to other ethnic groups through international collaborations.A state-of-the-art,surface-based preprocessing pipeline has also been introduced to improve *** images from patients with bipolar disorder and schizophrenia will be included to identify shared and unique abnormalities across diag-nosis *** addition,large-scale longitudinal studies targeting brain network alterations following antidepressant treatment,aggregation of diffusion tensor images,and the development of functional magnetic resonance imaging-guided neuromodulation approaches are *** these endeavours,we hope to accelerate the translation of functional neuroimaging findings to clinical use,such as evaluating longitudinal effects of antidepressant medications and developing individualized

关键词： major depressive disorder DIRECT R-fMRI database neuroimaging

Malnutrition and Quality of life in Chinese Cancer Patients: a Clinical Study of 23,994 Subjects

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Nutritional Oncology 2021年第1期6卷 16-32页

作者： hong Xia Xu Chun Hua Song zhen Ming Fu chang Wang Zeng Qing Guo Yuan lin Ying Ying Shi Wen Hu Yi Ba Su Yi li Zeng Ning li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai ping jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao li Jun Wen Ou Qing Chuan Zhao jian Xiong Wu Min Weng Qing Hua Yao Jiu Wei Cui Wei li Han ping Shi the Investigation on Nutrition Status and Clinical Outcome of Common Cancers(INSCOC)Group department of Nutrition Daping Hospital&Research Institute of SurgeryThird Military Medical UniversityChongqing 400042China department of Epidemiology College of Public HealthZhengzhou UniversityZhengzhou 450001HenanChina Cancer Center Renmin Hospital of Wuhan UniversityWuhan 430060HubeiChina Cancer Center of the First Hospital of Jilin university Changchun 130021JilinChina department of medical Oncology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhou 350014FujianChina department of Gastrointestinal Surgery Cancer Hospital Affiliated to Guangxi Medical UniversityNanning 530021GuangxiChina department of Surgery The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080GuangdongChina department of Clinical Nutrition West China Hospital of Sichuan UniversityChengdu 610041SichuanChina department of Gastrointestinal Oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjin Key Laboratory of Cancer Prevention and TherapyTianjin 300060China department of Nutrition and Metabolism of Oncology Affiliated Provincial Hospital of Anhui Medical UniversityHefei 230031AnhuiChina department of Clinical Nutrition the First Hospital of Hebei Medical UniversityShijiazhuang 050031HebeiChina department of Gastrointestinal Surgery Institute of Gastroenterologythe First Affiliated Hospital of Kunming Medical University 650032KunmingYunnanChina department of Clinical Nutrition the First People's Hospital of KashiKashi 844000XinjiangChina department of Clinical Nutrition Chongqing General HospitalChongqing 400014China department of Colorectal and Anal Surgery Huizhou Municipal Central HospitalHuizhou 516001GuangdongChina department of Radiation and medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 430071HubeiChina department of Oncology Xingtai People’s HospitalHebei Medical UniversityXingtai 054031HebeiChina Harbin medical university Cancer Hospital Harbin 150085HeilongjiangChina

Background Malnutrition is common in patients with cancer,and can negatively impact their quality of life(QoL)and even ***,there is currently no large data available on the prevalence of malnutrition in Chinese cancer *** study evaluated the prevalence of malnutrition and the QoL of Chinese patients with locoregional,recurrent or metastatic *** We conducted a nationwide observational,multi-center,hospital-based cross-sectional study within the Chinese Society of Nutritional Oncology(CSNO)*** of the patients were diagnosed with one of the following 18 different types of malignant tumors:lung cancer,gastric cancer,liver cancer,colorectal cancer,breast cancer,esophageal cancer,cervical cancer,endometrial cancer,nasopharyngeal carcinoma,malignant lymphoma,leukemia,pancreatic cancer,ovarian cancer,prostate cancer,bladder cancer,brain cancer,biliary tract malignant tumors or gastrointestinal stromal *** patients were enrolled from 72 hospitals located in different regions of *** patients’nutritional status was evaluated based on the body mass index(BMI),loss of bodyweight,laboratory measurements and patient generated-subjective global assessment(PG-SGA)*** cancer patients’physical status and QoL were assessed by the Karnofsky Performance Status(KPS)questionnaire and the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 questionnaire,*** From December 2013 to April 2016,23,994 patients hospitalized for cancer treatment(such as surgery,chemotherapy or radiotherapy)were enrolled in the *** patients included 12,494(52.9%)males and 11,124(47.1%)*** mean age was 55.8±13.7 *** proportions of patients in cancer stagesⅠ,Ⅱ,Ⅲ,Ⅳand uncertain were 11.5%,20.3%,27.5%,30.2%and 10.5%,*** the 23,994 inpatients,the proportions of patients who were underweight(BMI<18.5 kg/m2),normal(18.5 kg/m2

关键词： Nutritional status Nutritional assessment Malnutrition Patient generated subjective global assessment Body mass index Body weight loss Karnofsky Performance Status score Quality of life